The next-generation checkpoint pipeline grows behind Opdualag
Following BMS’s newly approved LAG3 blocker, the next-generation checkpoint pipeline grows to more than 100 candidates
It’s been a long road to the market for next-generation checkpoint inhibitors. BMS’s Opdualag may be the first to cross the finish line, but there’s a deep and growing pipeline of candidates behind.
On Friday, FDA approved an NDA for a fixed dose combination of relatlimab, an anti-LAG3 mAb from Bristol Myers Squibb Co. (NYSE:BMY), and the pharma’s marketed PD-1 inhibitor Opdivo nivolumab. ...
BCIQ Target Profiles
Inducible T cell co-stimulator (ICOS)
Lymphocyte-activation gene 3 (LAG3) (CD223)
T cell immunoglobulin and mucin domain 3 (TIM3) (HAVCR2)
T cell immunoreceptor with Ig and ITIM domains (TIGIT)
Tumor necrosis factor (TNF) receptor superfamily member 4 (OX40) (TNFRSF4) (CD134)
Tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB) (TNFRSF9) (CD137)